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Abstract
Background: CD44 and phosphorylated AKT (p-AKT) is a potentially interesting prognostic marker and therapeutic
target in pancreatic cancer. The expression of CD44 and p-AKT has been reported to correlate with poor prognosis
of pancreatic cancer in most literatures. The purpose of this study is to investigate the roles of CD44 and p-AKT in
pancreatic head cancer and their correlation with the prognosis of pancreatic head cancer patients.
Methods: Forty-eight pancreatic head cancer samples were collected dating from Jan. 2010 to Dec. 2012.
Immunohistochemistry was applied to test the expression of CD44 and p-AKT in pancreatic head cancer. The
clinical data of the patients were collected including their gender, age, the histology and location, lymph node
metastasis, and so on. The correlation between the CD44 expression and the clinicopathological factors of patients
with pancreatic head cancer was analyzed by the software SPSS 13.0.
Results: The positive rates of CD44 and p-AKT expression in the samples were 64.6 and 29.2 %, respectively. There
was a significant difference between the CD44 expression and the pancreatic cancer’ T staging, tumor node
metastasis (TNM) staging, lymph node metastasis (P < 0.05). The Cox proportional hazard model showed that CD44
and lymph node metastasis were independent prognostic factors.
Conclusions: CD44 was related to the distant metastasis and aggressive malignant behaviors of pancreatic head cancer.
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Background
Pancreatic cancer is a digestive tract malignant tumor with
poor prognosis because of difficult diagnosis and rapid de-
velopment, most of them located in the head of pancreas
[1]. Most pancreatic head cancer patients have peripan-
creatic nerve invasion and lymph node metastasis during
diagnosis, and 1-year survival rate is less than 20 % [2]. It
is necessary to explore the biological index for the early
diagnosis and prediction of pancreatic head cancer which
present as aggressive and recurrent malignancies.
Tumor invasion and metastasis involves the interaction
of multiple factors. Cancer stem cells (CSC), a subpopula-
tion of tumor cells, are responsible for tumor initiation,
growth, metastasis, and resistance to chemotherapy [3].
Some cell surface markers have been reported as CSC
markers in pancreatic cancers, such as CD44, CD133,
ALDH1, and ABCG2, and high expression of these markers
is usually considered an indicator of poor prognosis [4].
CD44, an important marker for CSC, is a membrane glyco-
protein involved in cell–cell and cell–extracellular matrix
adhesion as well as cell migration, differentiation, and sur-
vival. CD44 may be involved in invasion and metastasis by
regulating different signal transduction pathways, including
phosphorylated AKT (p-AKT) [5]. p-AKT phosphorylates
multiple proteins implicated in cellular processes leading to
induction of cell survival and inhibition of apoptosis. This
effect could be mediated by CD44. Previous studies demon-
strated that anti-CD44 mAb induces apoptosis by suppress-
ing the PI3K/Akt cell survival pathway [6].
Most scholars believe that the CD44 gene can be used
as a new tumor marker, which greatly facilitates the early
diagnosis of malignant tumor recurrence and metastasis
[7, 8]. Several studies have reported overexpression of
CD44 in subsets of pancreatic adenocarcinomas in 37–
80 % of the tumors investigated [9]. However, most of
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them focused on all sites of the pancreas. There is rela-
tively few data on CD44 expression in pancreatic head
adenocarcinomas.
In this study,CD44 and p-AKT were selected as
markers. Here, we used immunohistochemical (IHC)
method to detect the expression of CD44 and p-AKT in
the pancreatic head cancer tissues. The aim of the present
study was to examine the prognostic relevance of CD44
expression in pancreatic head adenocarcinomas.
Methods
Patients and specimens
Forty-eight pancreatic head cancer samples were collected
dating from Jan. 2010 to Dec. 2012. The clinical data of
the patients were collected including their gender, age, the
histology and location, lymph node metastasis, and so on.
Standard demographic, clinicopathological, and tumor-
specific data were collected retrospectively from hospital
records, and the disease stages of the patients were classi-
fied according to the 2010 AJCC pancreatic cancer tumor
node metastasis (TNM) staging system [10]. For the use
of these clinical materials for research purposes, informed
consent and approval from the Institute Research Ethics
Committee was obtained.
Immunohistochemistry and assessment
Four-micrometer sections of tissue were transferred to
an adhesive-coated slide, and our pathologists have
reviewed the slides to ensure that the tissues were con-
sistent with pancreatic ductal adenocarcinoma (PDAC).
Immunohistochemical staining to detect the expression
of CD44 and p-AKT in paraffin sections was performed
as described [11]. The quality of staining was judged in
the control material from different organs, on the basis
of the data available in the literature regarding gene/pro-
tein expression of CD44 and p-AKT in various tissue
types. The number of positively stained cells and the
intensity of positive staining were scored by two pathol-
ogists independently. Cases with different scores were
discussed to reach an agreement. The intensity of stain-
ing was evaluated semiquantitatively as negative (no
staining or staining in less than 10 % of cancer cells),
lowly positive (11–25 %), or strongly positive (>25 %).
Cells were considered positive only if CD44 and p-AKT
intensity was lowly or strongly. Otherwise, the sample
was considered negative. The immunostaining of each
tissue was assessed in five areas of the acquired images
of each tissue section, and the mean of these five scores
was calculated. The whole sections were also screened
at ×400 and ×1000 magnification, looking for features
such as nuclear/cytoplasmic staining, expression in ves-
sels, etc. The correlation between the expression of
CD44, p-AKT, and the clinicopathological factors of
patients with pancreatic cancer was analyzed.
Statistical analysis
All statistical analyses were done by using the SPSS 13.0
software package (SPSS; SPSS Inc., Chicago, USA). In
the set of IHC assay of paraffin-embedded tissue sam-
ples, the nonparametric test was used to estimate the
correlations between CD44, p-AKT, and clinicopatho-
logic characteristics. The Kaplan–Meier analysis module
was used for comparing survival rates between multiple
groups, and differences were measured using the log-
rank test. Multivariate analysis of prognostic factors was
performed using the Cox proportional hazard method.
The results are presented as the median survival in
months with 95 % confidence interval (CI), the relative
risk with 95 % CI, and the number of patients at risk. A
P value less than 0.05 was considered to be statistically
significant as indicated.
Results
Clinicopathologic characteristics and outcomes
By IHC analysis,31 (64.6 %) and 14 (29.2 %) paraffin-
embedded archival pancreatic tumor tissues showed a
positive staining for CD44 and p-AKT (Figs. 1 and 2).
Patients’ clinical data between the CD44-positive and
CD44-negative groups are listed in Table 1. Differences
in age, sex, differentiation, vascular invasion, and nerve
invasion between the two groups were not significant.
Most patients had stage II disease (50 %); 35.4 % of
patients had lymph node metastases. The majority of
tumors were poorly differentiated (75.0 %), and the
remaining tumors were well differentiated (10.4 %) and
moderately differentiated (14.6 %). Forty-three patients
received radical surgery. None of the patients received
preoperative chemotherapy or chemoradiotherapy.
Thirty followed by gemcitabine based postoperative ad-
juvant chemotherapy for patients with advanced stage
(T3/4 or N1-3). Five patients were found to have liver or
Fig. 1 The expression of CD44 in pancreatic head cancer specimens
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peritoneal metastases during operation and received pal-
liative operation, followed by gemcitabine-based pallia-
tive chemotherapy.
The nonparametric test was used for the relationship
between the expression of CD44, p-AKT, and clinical-
pathological factors. CD44-positive tumors were more
likely associated with T stage (P = 0.035), TNM staging
(P = 0.002), and lymph node metastasis (P = 0.011),which
suggested that overexpression of CD44 correlated with a
more aggressive phenotype in pancreatic head cancer. In
pancreatic head cancer, p-AKT-positive cells were identi-
fied in most cases with various intensities in the positive
cell population. However, to compare with CD44 expres-
sion patterns, we did not find any significant correlations
with p-AKT expression.
Univariate analysis of prognostic factors of pancreatic
head cancer
All the patients were followed up to get the survival
data. Overall survival time was defined as the time from
surgery until death (living patients were censored at the
Fig. 2 The expression of p-AKT in pancreatic head cancer specimens
Table 1 Relationship between expression of CD44, p-AKT, and clinicopathological parameters
Variable Number CD44 P p-AKT P
Positive Negative Positive Negative
LNM 0.011
Negative 31 15 16 6 25 0.056
Positive 17 15 2 8 9
T classification 0.035
T1-2 18 8 10 6 12 0.632
T3-4 30 23 7 8 22
TNM stage
I + II 28 13 15 0.002 14 14 0.613
III + IV 20 18 2 10 10
Differentiation
Well + moderately 12 9 3 0.492 3 9 0.516
Poorly 36 22 14 11 25
Vascular invasion
Negative 45 28 17 0.303 13 32 0.904
Positive 3 3 0 1 2
Nerve invasion
Negative 42 27 15 0.910 11 31 0.367
Positive 6 4 2 3 3
Age (years)
≥60 17 10 7 0.752 5 12 0.978
<60 31 21 10 9 22
Sex
Male 30 20 10 0.762 9 21 0.871
Female 18 11 7 5 13
LNM lymph node metastasis
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time of their last follow-up). The median follow-up time
was 39 months, and thirty patients had died at the last
follow-up time. We examined the correlation of CD44
expression with patients’ survival of 48 pancreatic head
cancers that had survival data available by Kaplan–Meier
survival analysis (see Table 2). The median overall sur-
vival time of patients in the CD44-negative group were
30 months, whereas that in the CD44-positive group
was only 18 months, and the difference between the two
groups was significant (hazard ratio = 0.284; 95 % confi-
dence interval, 0.125–0.407; P = 0.001). Log-rank test
showed that T staging, lymph node metastasis, and
neural invasion also significantly affect the prognosis of
pancreatic head cancers. Advanced T staging, lymph
node metastasis, and neural invasion positive patients
survived shorter, and the difference is significant (P <
0.05). The survival difference between TNM staging, dif-
ferentiation, vascular invasion, age, and sex were not sta-
tistically significant. The survival curve of the effects of
CD44 expression on pancreatic head cancer is shown in
Fig. 3. The results suggest that overexpression of CD44
correlates with poor prognosis in pancreatic head
cancer.
Since tumors expressing CD44 were significantly more
likely to be lymph node metastasis than CD44-negative
tumors, the joint effects of CD44 status and lymph node
metastasis on survival were assessed by Kaplan–Meier
analysis, stratifying for CD44 status (positive vs. negative)
and lymph node metastasis (positive vs. negative) (Fig. 4).
Patients whose tumors overexpressed CD44 and lymph
node metastasis (LMN) had significantly poorer survival
than CD44 and LMN groups (P = 0.001).
Multivariate analysis of prognostic factors of pancreatic
head cancer
In a multivariable Cox proportional hazard model, which
included lymph node metastasis, clinical stage, CD44 ex-
pression, and nerve invasion, CD44-positive tumors and
lymph node metastasis independently predicted poor
prognosis. Patients with CD44-positive expression had
worse overall survival compared with patients with
CD44-negative expression (hazard ratio = 0.199; 95 %
confidence interval, 0.049–0.965; P = 0.045) (Table 3).
There was a strong correlation between CD44 expres-
sion and lymph node metastasis (P = 0.002). These data
suggest that the CD44 and lymph node metastasis were
the independent prognostic indicator.
Discussion
Because of its poor prognosis, pancreatic cancer is one
of the four or five most common causes of cancer mor-
tality in developed countries [12]. Lymph node metasta-
sis is a poor prognostic factor in patients with pancreatic
Table 2 Univariate analysis of prognostic factors of pancreatic head cancer
Hazard ratio 95 % CI P value
CD44 (positive/negative) 0.284 0.125–0.407 0.001
p-AKT (positive/negative) 1.094 0.696–1.719 0.696
Lymph node metastasis (yes/no) 0.468 0.290–0.756 0.013
T classification (T1-2/T3-4) 0.446 0.283–0.702 0.000
TNM stage (I + II/III + IV) 1.216 0.772–1.916 0.393
Differentiation (well + moderate/poor) 1.019 0.650–1.599 0.984
Vascular invasion (yes/no) 1.513 0.965–2.371 0.087
Nerve invasion (yes/no) 0.408 0.246–0.676 0.000
Age (<60/≥60) 1.454 0.930–2.282 0.873
Sex (male/female) 1.255 0.798–1.974 0.345
Fig. 3 Effects of CD44 expression on pancreatic head cancer survival
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cancer. The negative effect of lymph node metastasis as
a prognostic factor for patients undergoing surgical re-
section for pancreatic head adenocarcinoma has been
well established [13]. Currently, the only biomarker used
in the routine management of pancreatic head cancer is
CA19-9. But approximately 5 % of the population do not
secrete CA19-9 [14]. Therefore, much effort has focused
on enhancing the performance of CA19-9 by including
it within larger panels of markers.
CD44 has been studied for three decades, but no con-
sensus opinion on cancer progression has been reached
until now. CD44 is the major hyaluronan receptor. Inva-
sive and metastatic growth can be mediated through the
interaction of cell surface CD44 with hyaluronan or
cell–cell interactions [15]. CD44 was revealed to be a
target of the Wnt pathway, which is accepted as a key
pathway for the stemness maintenance of cancer stem
cell markers [16]. Recent clinical studies have shown
high levels of CD44 expression in gastric cancer, colorec-
tal cancer, and nonsmall cell lung cancer [17–19]. It was
reported that overexpression of CD44 indicated bad clin-
ical features and poor prognosis. Moreover, a large body
of epidemiological, clinical, and molecular evidence sug-
gests that CD44 was overexpressed in pancreatic cancer
cell lines and pancreatic tumors and plays an important
role in the carcinogenesis and progression of pancreatic
cancer [20, 21]. Cell surface expression of CD44 plays an
important role in the defense against reactive oxygen
species, leading to ultimate survival of CSCs. Jiang et al.
[22] provide in vivo evidence that CD44 is required for
pancreatic cancer invasion and CD44 regulates pancre-
atic cancer cell invasion through MT1-MMP. Li et al.
[23] also reported that increased CD44v expression was
found in metastatic pancreatic carcinoma in human
tumor tissue. Clinical analysis showed that CD44v6+
and CD44v9+ were correlated with lymph node metasta-
sis, liver metastasis, and TNM stage.
In the present study, we show that CD44 is overex-
pressed in pancreatic head cancer tissues. Importantly,
we found that overexpression of CD44 correlated with
advanced clinical stage and positive lymph node metas-
tasis. Our previous study also showed that stable knock-
down of CD44 expression in pancreatic cancer cells can
inhibit proliferation and migration in pancreatic cancer
cells. This provide preliminary direct evidence for the
possibility of CD44 regulating the metastasis of pancre-
atic cancer. These data clearly suggest that CD44 not
only plays a key role in tumorigenesis but may also be
involved in the progression and metastasis of pancreatic
head cancer.
Lymph node involvement in pancreatic head cancer is
one of the strongest adverse prognostic factors, with 5-
year survival rate falling significantly to less than 10 % in
cases of metastatic lymph node. Many articles have
proved that CD44 was closely related with lymph node
metastasis [24], which was well supported by our report.
The results of our report supported that the function of
the lymph node metastasis might be dependent on
CD44. The finding in the present study that CD44 ex-
pression correlates with a favorable prognosis in pancre-
atic cancer can be explained by the fact that there is a
significant association between CD44 expression and
lymph node metastasis. In human pancreatic cancer tis-
sue, lymph node metastasis overexpressed CD44 while
there was less expression of CD44 in negative lymph
node metastasis. More than 80 % of tumors with lymph
node metastasis showed overexpression of CD44. This
result is consistent with previous studies. For more de-
tailed analysis, we compared between the patients with
CD44-positive and lymph node metastasis. We found
that the subgroup of patients with CD44-negative/no
lymph node metastasis tumors had a significantly better
survival compared to patients with CD44-positive/lymph
node metastasis tumors. Multivariate Cox proportional
hazard model analysis showed the strong statistical asso-
ciation between CD44 expression and lymph node
Fig. 4 Effects of CD44 expression and lymph node metastasis on
pancreatic head cancer survival
Table 3 Multivariate analysis of prognostic factors of pancreatic
head cancer
Hazard ratio 95 % CI P value
CD44 (positive/negative) 0.199 0.049–0.965 0.045
T classification (T1-2/T3-4) 0.125 0.117–0.891 0.059
Lymph node metastasis (yes/no) 0.299 0.015–1.552 0.023
Nerve invasion (yes/no) 0.119 0.043–0.327 0.933
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metastasis. Thus, the presence of CD44 expression in
these tumors appears to be a marker of favorable prog-
nosis closely linked to the lymph node metastasis.
CD44-positive cells constitute the resistant cell popula-
tion, and CD44 could be a therapeutic target to overcome
the drug resistance for pancreatic cancer. Using an anti-
body targeting CD44s in mice with human pancreatic
tumor xenografts, Li et al. [25] found that anti-CD44s
reduced tumor growth and metastasis. The antibody also
reduced the number of tumor initiating cells in cultured
pancreatic cancer cells and inhibited cell proliferation and
survival signaling.
The relationship between the expression of p-AKT and
tumor prognosis remains controversial [26, 27]. Liu et al.
[28] showed that the positive expression rate of p-AKT in
pancreatic cancer was 83.8 %. The related research in
most of pancreatic cancer, high expression of p-AKT, is
correlated with poor prognosis [29], but there are also
some research considered p-AKT-positive staining is cor-
related with better prognosis. We did not find any signifi-
cant correlations between high p-AKT expression and
certain clinicopathological findings. The limitations could
be due to the limited number of samples in our study.
Further studies are needed to explore the mechanisms of
p-AKT in pancreatic head cancer.
Conclusions
In summary, overexpression of CD44 was associated with
poor overall survival in patients with pancreatic head can-
cer. However, more prospective studies are needed to ex-
plore the prognostic value of CD44 in pancreatic head
cancer. With the thoroughly research in the mechanism
and regulation pathway, CD44 will play a greater role in
tumor diagnosis, treatment, and prognosis.
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